

Index

A

- Adjuvant treatments in autoimmune blistering diseases, 244, 246–251, 255, 256
- Adolescent, 188, 196, 216, 223, 225, 226
- Anchoring fibrils, 135–138, 140, 144, 189
- Antibody, 2–4, 6, 10–12, 25–27, 29, 31, 33, 35, 45, 46, 48–51, 58, 65, 66, 88, 90, 117, 118, 121, 124, 125, 127, 128, 135, 138, 140, 143, 150, 152, 159, 160, 165, 169, 178, 180, 182, 183, 185, 187–194, 195, 208, 218, 220, 222, 224, 225, 227, 234
- Antigen, 25, 50, 58, 121, 122, 128, 138, 140, 150, 176, 178, 180, 192, 194
- Antihistamines, 152, 159, 255–256
- Autoantibody, 2, 4, 10, 20, 24, 25, 29, 45, 58, 69, 89, 127, 135–140, 144, 150, 155, 157, 160, 176, 178, 180, 184, 187, 188, 192, 194, 218, 222, 225, 245
- Autoimmune, 136, 137, 139, 140, 150, 160, 171, 194, 197
- Autoimmune blistering disease, 41, 65, 69, 101, 102, 144, 150, 156, 175–202, 205–228, 244
- Autoimmune bullous, 1, 135, 140, 142, 143, 176, 179, 182, 187, 188, 196, 213, 214, 228
- Azathioprine, 5–8, 10–13, 27, 28, 30, 32, 35, 51, 61–64, 66, 68, 82–84, 87, 88, 104, 111, 113, 126–128, 142, 153–156, 158, 180–182, 190, 200, 211, 213–215, 220, 221, 223, 226, 227, 246, 250

B

- Basement membrane, 45, 104, 117, 121, 150, 152, 188
- Blistering, 1, 42, 49, 75, 100, 111, 112, 134, 135, 152, 153, 155, 157–159, 209, 211, 212, 224, 252–254
- Bullous lupus, 182, 187–192, 197
- Bullous pemphigoid (BP), 46, 47, 57–69, 81, 100, 101, 104, 126, 135–140, 142, 150, 155–157, 176–178, 181, 185, 187–189, 214, 217–222, 244–246, 249, 251, 253–255
- Bullous pemphigoid 180 antigen (BP180), 47, 50, 58, 65, 69, 121, 150, 152, 157, 160, 176, 178–180, 182, 218

C

- Cataracts, 7, 239
- CBDC. *See* Chronic bullous disease of childhood (CBDC)
- Child, 2, 100, 118, 121–128, 138, 142, 153, 159, 166, 176, 179–181, 185, 188, 191, 196, 199, 205–228
- Chronic bullous disease of childhood (CBDC), 136, 138, 206–216, 221, 222
- Colchicine, 32, 33, 106, 125–128, 134, 137, 140, 169, 183, 195, 196, 199–201, 210, 214, 223, 228
- Corticosteroids, 3, 5–11, 13, 14, 26, 27, 29, 31–33, 35, 36, 50–52, 62, 64, 77, 79, 82–86, 88–91, 106–109, 111, 113, 124–127, 152–153, 155, 158–160, 178–181, 185–187, 190, 191, 194–196, 200, 201, 208–215, 218–227, 233–240, 244–249, 255

Cyclophosphamide, 6–10, 12, 13, 27,
29–30, 51, 52, 66, 67, 83, 86–89,
91, 106, 110, 111, 113, 127, 128,
142, 154, 158, 215, 226, 227
Cyclosporine, 63–64, 77

D

Dapsone, 5, 6, 9, 26, 50–52, 61, 81–83,
91, 104, 106, 107, 109, 111, 112,
124–125, 128, 142, 153, 154, 158,
169–171, 179–183, 186, 187, 190,
191, 194–196, 198–201, 208–217,
219, 220, 222–223, 247, 250
Dermatitis herpetiformis (DH), 42, 46, 50,
81, 138, 163–171, 187, 188, 208,
215–217, 253, 255
Desmoglein, 2, 4, 20, 45, 48, 178,
192, 194, 225

E

Elixirs, 247–249, 251
Epidermolysis bullosa (EB),
135, 137, 138, 222
Epidermolysis bullosa acquisita (EBA),
100, 104, 133–144, 160, 188–190,
214, 218, 222, 223, 248

F

Food and nutrition, 252–253

G

Glucocorticoid-induced osteoporosis
(GIOP), 235–237
Glucocorticoids, 7, 14, 83, 125, 234–240
Gluten sensitive enteropathy, 164

H

Hydroxychloroquine, 35
Hyperglycemia, 236

I

IgA pemphigus, 1, 46, 183, 192–197
Immunobullous, 117, 187
Immunobullous disease, 50, 127, 128, 139,
142, 211, 217, 254
Immunofluorescence, 42, 46, 51, 167, 169,
182, 197, 224

Immunosuppressives, 5–8, 10, 11, 13,
26, 29, 32, 33, 61, 65, 66, 68, 69,
78, 80–89, 91, 111, 113, 124, 126–127,
142–144, 154, 180, 181, 190, 191, 201,
211, 223, 225, 227, 239, 254
Infection control, 254–255
Inflammation, 76, 77, 80–87, 90, 101, 102,
122, 185, 234, 235, 249
Intralesional corticosteroids, 6, 227, 248
Intravenous immunoglobulin (IVIG),
6, 9, 11, 13, 28–29, 35, 51,
52, 65, 69, 79, 89–91, 104,
108–111, 113, 127, 143–144,
154–156, 158, 211, 213–215,
219–221, 223, 226, 227

J

Juvenile, 67, 199, 226

L

Lichen planus (LP),
100, 176–182, 184–187, 253
Lichen planus pemphigoides (LPP),
176–185
Linear IgA bullous disease,
46, 47, 117–129, 188, 189, 206, 250
Linear IgA disease of childhood, 206
Local treatments in autoimmune blistering
diseases, 243–256
LP. *See* Lichen planus (LP)

M

Minocycline, 61, 68, 80, 104,
105, 107, 108, 246, 251
Mucous membrane, 1, 6, 50, 75, 76,
100–103, 112, 118, 137, 138,
150, 156, 157, 192, 197, 207,
209, 216, 217, 222, 224
Mycophenolate mofetil (MMF), 6–8, 10,
11, 13, 27–28, 30, 33, 35, 51, 62,
63, 68, 83–87, 91, 104, 105, 107–109,
111, 113, 126, 182, 190, 191, 195,
200, 211, 213–215, 219–221, 223,
226, 227, 250

N

Neonatal pemphigus, 223, 225
Niacinamide, 61, 126, 128, 179, 219, 246
Non-steroidal topical therapies, 249–250

O

- Ocular cicatricial pemphigoid,
75–91, 118, 127, 250
- Omalizumab, 66–67, 69
- Osteonecrosis, 236, 237

P

- Pemphigoid gestationis (PG), 149–160, 256
- Pemphigus foliaceus (PF), 1, 9, 19–36,
41, 42, 45–47, 49, 51, 192,
223–227, 245, 250
- Pemphigus herpetiformis (PH),
1, 20, 21, 24–26, 41–53
- Pemphigus vulgaris (PV), 1–14, 21,
27–33, 35, 36, 41, 45–49, 51,
89, 102, 187, 196, 215, 223–227,
245, 247, 250, 251, 254
- PG. *See* Pemphigoid gestationis (PG)
- Plasmapheresis, 10–11, 13, 28, 31, 51, 64,
65, 68, 88–89, 143, 154, 155, 158
- Pregnancy, 84, 150, 152–155, 158, 159, 256

R

- Rituximab (RTX), 6, 11–14, 31–32, 35, 51,
52, 65–66, 69, 79, 89–91, 104, 108,
109, 111, 113, 124, 125, 127, 128,
143, 156, 158, 182, 190, 191, 214,
215, 220, 221, 226, 227

S

- Side effects of local corticosteroids, 249
- Sneddon-Wilkinson, 196

- Subcorneal pustular dermatosis (SPD),
183, 192, 194–202
- Systemic steroids, 7, 60, 61, 63, 64,
67–69, 105, 108, 142, 178,
179, 181–183, 185, 186, 194,
201, 211, 220, 244, 246, 250, 255

T

- Tetracyclines, 32, 33, 61, 68, 80–81,
105, 126–128, 158, 169, 180,
246, 249, 251
- TNF- α inhibitors. *See* Tumour necrosis
factor- α (TNF- α) inhibitors
- Topical corticosteroids, 5, 33, 35, 50,
77, 107, 109, 179, 180, 194,
209, 212, 218, 219, 221,
223–225, 227, 244–249
- Topical steroids, 59–61, 63, 65, 152, 157,
179–181, 217, 244–247, 249
- Treatment, 3, 25, 45, 59, 76, 100, 118,
140, 152, 169, 178, 208, 234, 244
- Tumour necrosis factor- α (TNF- α) inhibitors,
12–13, 200, 201
- Type VII collagen,
121, 138, 160, 182, 188, 189

U

- Ultraviolet light, 45, 122, 253–254

V

- Vaccines, 185, 217, 255